HPV Vaccine's Long-Term effects under the microscope in costa rica

NCT ID NCT00867464

First seen Jun 25, 2026 · Last updated Jul 30, 2026 · Updated 4 times

Summary

This study follows over 8,600 women in Costa Rica who received the HPV vaccine (types 16 and 18) years ago, plus unvaccinated controls, to see how well the vaccine protects over time. Researchers are checking for cervical lesions, immune markers, and any increase in infections from other HPV types. The goal is to understand the vaccine's long-term benefits and risks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
HPV vaccine (against types 16 and 18)
What this could lead to
If successful, this study could confirm how long the HPV vaccine protects against cervical cancer and related diseases, and whether it causes any unexpected shifts in infection patterns.
What could go wrong
This is an observational follow-up, not a new treatment test. Results may show waning immunity or increased lesions from other HPV types not covered by the vaccine.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANAL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Agencia Costarricense de Investigaciones Biomédicas (ACIB)

    Liberia, Guanacaste Province, 50101, Costa Rica

More trials for these conditions

Other studies related to the condition(s) this trial covers.